Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 3)

Link copied
Case Copied 32 min read

FEDERAL COURT OF AUSTRALIA

Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 3) [2020] FCA 222

File numbers: NSD 121 of 2012
NSD 837 of 2015
Judge: YATES J
Date of judgment: 28 February 2020
Catchwords: PRACTICE AND PROCEDURE – enforcement of undertakings as to damages - leave to amend pleadings to withdraw admissions – factors relevant to the exercise of discretion – leave granted
Legislation: Federal Court Rules 2011 (Cth) r 26.11
National Health Act 1953 (Cth)
Cases cited:

Australian Competition and Consumer Commission v Construction, Forestry, Mining and Energy Union [2007] FCA 1390

Celestino v Celestino [1990] FCA 299

Centrestate Exports Pty Ltd v Amarantos Shipping Co Ltd [2005] SASC 158

Cropper v Smith (1884) 26 Ch D 700

Jeans v Commonwealth Bank of Australia [2003] FCAFC 309; 204 ALR 327

Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2019] FCA 230

Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2018] FCA 1556

Date of hearing: 11 and 17 September 2019
Registry: New South Wales
Division: General Division
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Category: Catchwords
Number of paragraphs: 66
Counsel for the Applicants/Appellants: Mr S M Nixon SC and Mr J J Hutton
Solicitor for the Applicants/Appellants: Jones Day
Counsel for the Respondents: Mr S G Habib SC and Mr A R Lang
Solicitor for the Respondents: Wrays Lawyers

ORDERS

NSD 121 of 2012

BETWEEN:

OTSUKA PHARMACEUTICAL CO., LTD

First Applicant/First Appellant

BRISTOL-MYERS SQUIBB COMPANY

Second Applicant/Second Appellant

AND:

GENERIC HEALTH PTY LTD (ACN 110 617 859)

First Respondent

COMMONWEALTH OF AUSTRALIA

Other

JUDGE:

YATES J

DATE OF ORDER:

28 FEBRUARY 2020

THE COURT ORDERS THAT:

1.Leave be granted to Otsuka/BMS to withdraw paras 28, 29, 30 and 31(a) of the Response to Statement of Particulars of Claim for Damages filed in Generic Health’s enforcement proceedings, and to file an amended Response to Statement of Particulars of Claim for Damages in the form annexed to their interlocutory application dated 17 April 2019.

2.Otsuka/BMS pay Generic Health’s costs thrown away by reason of the amendments sought.

3.Otsuka/BMS pay the costs of the application to amend.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


ORDERS

NSD 837 of 2015
BETWEEN:

OTSUKA PHARMACEUTICAL CO., LTD

First Applicant/First Appellant

BRISTOL-MYERS SQUIBB COMPANY

Second Applicant/Second Appellant

AND:

GENERIC HEALTH PTY LTD (ACN 110 617 859)

First Respondent

COMMONWEALTH OF AUSTRALIA

Other

JUDGE:

YATES J

DATE OF ORDER:

28 FEBRUARY 2020

THE COURT ORDERS THAT:

1.Leave be granted to Otsuka/BMS to withdraw paras 30, 31, 32 and 33(a) of the Response to Statement of Particulars of Claim for Damages filed in Generic Health’s enforcement proceedings, and to file an amended Response to Statement of Particulars of Claim for Damages in the form annexed to their amended interlocutory application dated 17 September 2019.

2.Otsuka/BMS pay Generic Health’s costs thrown away by reason of the amendments sought.

3.Otsuka/BMS pay the costs of the application to amend.

Note:   Entry of…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2020] FCA 222
Decision Date

CaseChat Overview and Summary

In the matter of Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 3), the Federal Court of Australia was asked to determine whether Otsuka/BMS should be granted leave to amend their pleadings to withdraw admissions made in relation to potential damages. This case revolves around the dispute between Otsuka/BMS and Generic Health over alleged patent infringement and the potential financial implications of the interim injunction granted in favour of Otsuka/BMS. The primary legal issue before the court was whether Otsuka/BMS should be permitted to withdraw admissions relating to the counterfactual scenario that, had the interim injunction not been granted, Generic Health would have sought and obtained Pharmaceutical Benefits Scheme (PBS) listing for its products on 1 April 2012 and commenced selling those products on the PBS market on that day.

The court considered several factors relevant to the exercise of discretion in granting leave to amend pleadings. Firstly, the court noted that the "forensic landscape" in this case did not change with the decision in Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2018] FCA 1556; 136 IPR 8, as Otsuka/BMS were already aware from the outset of the proceedings that Generic Health's claim was, in part, a loss of opportunity case. The court emphasised that the particulars provided by Generic Health in the appendix to its Statements of Particulars of Claim for Damages made it clear that Otsuka/BMS had admitted to unqualified facts, not merely the existence of opportunities. Furthermore, the court found that the potential delay and additional evidence required by Generic Health to counter the admissions did not outweigh the need for the court to ensure that the proceedings were justly decided.

In light of the above considerations, the court granted leave to Otsuka/BMS to withdraw the specified admissions and file an amended Response to Statement of Particulars of Claim for Damages. The orders of the court included granting leave for the amendments sought, with Otsuka/BMS to pay Generic Health's costs incurred due to the amendments and the costs of the application to amend.

Orders

Orders of the court

1. Leave be granted to Otsuka/BMS to withdraw paras 30, 31, 32 and 33(a) of the Response to Statement of Particulars of Claim for Damages filed in Generic Health’s enforcement proceedings, and to file an amended Response to Statement of Particulars of Claim for Damages in the form annexed to their amended interlocutory application dated 17 September 2019.

2. Otsuka/BMS pay Generic Health’s costs thrown away by reason of the amendments sought.

3. Otsuka/BMS pay the costs of the application to amend.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Generic Health opposes Otsuka/BMS’s applications to amend.THE EVIDENCE The solicitor for Otsuka/BMS, Mr Emmerig, has made an affidavit, sworn on 2 September 2019, in which he has deposed to his belief that there is a proper basis for Otsuka/BMS putting in issue the counterfactual allegations that, but for the interim injunction that was granted (and continued), Generic Health would have sought and obtained PBS listing of the GH products on 1 April 2012 and would have commenced to sell those products on the PBS market on that day. The steps in Mr Emmerig’s reasoning, and the facts which Otsuka/BMS would seek to prove and the submissions it would seek to make, are as follows: (a)Generic Health anticipated that it would be restrained from infringing the patent in suit. It understood that the balance of convenience weighed strongly in favour of originator brands and courts had routinely granted interim injunctions in favour of protecting patent rights. Mr de Alwis, Generic Health’s General Manager, was aware in February 2012 that a generic competitor had been restrained from supplying its aripiprazole products by an order made by the Court on 20 October 2009.(b)On 14 February 2012, Generic Health’s Managing Director, Mr Upiter, sent an email to Mr de Alwis stating that Generic Health’s worst case scenario (i.e., if Otsuka/BMS were unsuccessful in obtaining interim injunctive relief but successful in obtaining final injunctive relief) was a liability to them for the “the 16% price drop which could apply for anywhere from 4 months to 24 months at a best estimate”, equating to $1.5 million to $9 million, plus litigation costs. Mr Emmerig argued that this email suggests that Generic Health may have been proceeding on the misunderstanding that the automatic 16% statutory price reduction could easily or routinely be reversed, thus limiting Generic Health’s liability exposure. Generic Health sought approval from its board members to list the GH products on the PBS on 1 April 2012 on the basis of this understanding of Generic Health’s potential liability. On 14 February 2012, a communication was sent to Generic Health’s board seeking approval to apply to list the GH products on the PBS on the basis that a 16% price reduction would be reversed within three to four months, and exposure to liability would only be for a limited period of time.(c)At the time, Generic Health was unprofitable. Its accounts suggest that it would not have been in a position to carry an exposure of liability to Otsuka/BMS had the statutory price reduction been triggered.(d)At the time, Generic Health had liquidity concerns.(e)In Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2018] FCA 1556; 136 IPR 8 (Sigma v Wyeth), Jagot J held that a claim for compensation on an undertaking as to damages, such as in the present case, should be considered on a “loss of opportunity” basis. This requires the Court to assess the extent of the probability or possibility that PBS listing would have been sought and obtained for the products in question.

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established

Generic Health submits further that a withdrawal of the admissions now will occasion delay in the proceedings. It submits that it will be necessary for it to adduce evidence in support of the facts that would be in issue. It submits that it is no answer to say that it has already filed affidavit evidence that bears upon those facts when a withdrawal of the admissions will require it to adduce sufficiently detailed evidence of the relevant facts. CONSIDERATION I do not accept that the “forensic landscape” in this case changed with the decision in Sigma v Wyeth, in the sense that, for the first time, Otsuka/BMS were met with an unforeseen and new legal development, or were otherwise alerted to the fact that they had to meet a case for damages assessed on a loss of opportunity basis. From its inception, Generic Health’s claim against Otsuka/BMS has been particularised as, in part, a loss of opportunity case. The appendix to Generic Health’s Statements of Particulars of Claim for Damages provides the following particulars: 1.Loss of the opportunity:(a) to be the first entrant into the market in Australia for generic products containing aripiprazole by selling its GH Products from 1 April 2012;(b) to have the GH PBS Products listed on the Schedule of Pharmaceutical Benefits pursuant to the Pharmaceutical Benefits Scheme (“PBS”), from 1 April 2012;(c) to be the first generic pharmaceutical company to sell generic products containing aripiprazole in the PBS market by selling the GH PBS Products in Australia from 1 April 2012;(d) to sell the GH Products during a period when sales of Respondents’ Registered Aripiprazole Products were higher in volume than on and from 1 December 2016;(e) to penetrate the market for other generic products and to sell additional products; (f) to sell to new customers (such as pharmacies or pharmacy buying groups); and(g) to strengthen relationships with existing customers. These particulars could not have escaped Otsuka/BMS’s attention. Although sub-paras 1(b) and (c) of the appendix refer to the “loss of opportunity” to obtain PBS listing, and the “loss of opportunity” to sell the GH products on the PBS market from 1 April 2012, paras 30 and 31(a) of the Statement of Particulars of Claim for Damages filed in the primary proceeding, and paras 32 and 33(a) of the Statement of Particulars of Claim for Damages filed in the appeal proceeding, plead unconditional “facts”, not simply “opportunities”. Despite a submission by Otsuka/BMS in oral argument to the contrary, I do not think that these allegations take their colour from sub-paras 1(b) and (c) of the appendix, such that Otsuka/BMS should be taken as having admitted no more than the existence of opportunities, as opposed to facts simpliciter. If opportunities alone have been admitted, it is difficult to understand why the present applications to withdraw the admissions have been made. Indeed, the correspondence to which I have referred makes it abundantly clear that Otsuka/BMS understood that they had admitted unqualified facts, not simply the existence of opportunities.